Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
Yael Kusne(WinnMed), Rafaël Fonseca(Mayo Clinic in Arizona), P. Leif Bergsagel(Mayo Clinic in Arizona), Mariano Arribas(Mayo Clinic Hospital), Craig B. Reeder(Mayo Clinic in Arizona), Julie Rosenthal(WinnMed), Molly Klanderman(Mayo Clinic in Florida), Julia E. Wiedmeier(Mayo Clinic Hospital), Rodrigo Fonseca(WinnMed), Jeremy T. Larsen(City of Hope)
Cited by 1
Related Papers
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
|Mayo Clinic Proceedings|2009|625
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Ductal Carcinoma in Situ of the Breast
|Annals of Internal Medicine|1997|245